

ADVISORY COMMITTEE
of the Connecticut Bioscience Innovation Fund
Minutes – Regular Meeting
Wednesday, July 15, 2015

A regular meeting of the **Connecticut Bioscience Innovation Fund Advisory Committee** (the “Committee”) was held on July 15, 2015, at the office of Connecticut Innovations, 865 Brook Street, Rocky Hill, CT.

Call to Order: Noting the presence of a quorum, Matthew McCooe, Chief Executive Officer Connecticut Innovations, and Chairperson of the Advisory Committee, called the meeting to order at 10:08 a.m.

Committee members present: Matt McCooe; Marc Lalande, Ph.D. (by phone); Alan Mendelson; Commissioner Catherine Smith; Bill LaRochelle, Ph.D.; Edmund Pezalla, M.D. (by phone); Charles Lee, Ph.D.; and Eleanor Tandler.

Other Attendees: Philip Siuta (CI); Margaret Cartiera, Ph.D. (CI); Ariel Drew (CI); Carrie Collins White (CI); Leslie Larson (CI); David Wurzer (CI); Whitney Harris Brown, Ph.D. (CI) (by phone); Tim Shannon, M.D. (Canaan Partners); Dennis Wright, Ph.D. (UConn); Craig Crews, Ph.D. (Yale) (by phone).

Mr. McCooe, newly hired Chief Executive Officer of CI, introduced himself to the Advisory Committee. He thanked the CBIF Advisory Committee and the BioInnovation CT team for their work and dedication to the Fund.

Approval of Minutes

Mr. McCooe asked the Advisory Committee members to consider the minutes from the June 3, 2015 meeting.

Upon a motion made by Commissioner Smith, seconded by Dr. Lee, the Advisory Committee members voted in favor of adopting the minutes from the June 3, 2015 meeting as presented. VOTE: 6-0-2 (In favor: Lalande, Smith, LaRochelle, Mendelson, Tandler, Pezalla; Abstained: Lee, McCooe).

Strategic Initiative: PITCH Follow-Up Discussion

Dr. Lalande was excused from the PITCH discussion.

Dr. Cartiera reviewed the PITCH strategic initiative, as presented to the Committee at the April 15, 2015 meeting. She gave a brief summary of the proposed project, including the project’s objectives and anticipated milestones. Dr. Cartiera summarized the motion made in support of PITCH, which was voted on by the Committee at the June 3, 2015

meeting. She introduced Dr. Crews and Dr. Wright, who are leading PITCH efforts at their respective universities, and explained that Dr. Crews requested an opportunity to speak to the Committee regarding the project's approved contingencies. Dr. Crews discussed in detail why each contingency raised concerns and posed limitations to the development of PITCH. Specifically, Dr. Crews discussed the project's timeline as well as an anticipated self-sustaining business model.

Dr. Cartiera opened the meeting to public comment.

A lengthy discussion ensued regarding the project's three year timeline and proposed milestones. Several questions were raised by the Committee regarding the project's deliverables, as well as research development, over the lifetime of PITCH.

Ms. Tandler asked for details regarding intellectual property and royalty structures. A discussion ensued on the return on investment and revenue structure of the project. Business development and workflow expectations of PITCH were discussed at length. The Committee agreed that the PITCH effort should reflect a CRO-like model and strive to include others outside of the university as soon as possible.

Following the discussion and consensus on reasonable expectations of PITCH, Dr. Cartiera asked the Committee to revise the motion for approval of PITCH, as taken at the June 3, 2015 meeting.

Upon a motion made by Commissioner Smith, seconded by Ms. Tandler, the Advisory Committee members voted in favor of approving PITCH for \$9,999,995 over three (3) years; funding is to be tranced on an annual basis contingent upon project milestone completion. Project milestones are subject to adjustments and revisions over the lifetime of the project, as acceptable by the CBIF team. VOTE: 7-1-0 (In favor: Mendelson, Smith, LaRochelle, McCooe, Tandler, Pezalla, Lee; Recused: Lalande).

Quarter 1 2015 Funding Opportunities

Dr. Lalande joined the meeting.

- 544—GestVision

Dr. Cartiera introduced the proposed project. She reviewed the risks and benefits of the technology; the current stage of development; investments the company has received to date and the opportunity for CBIF's investment to be leveraged in the near future.

A question was asked regarding the investment structure and the possibility of return. A discussion ensued.

Connecticut Bioscience Innovation Fund Advisory Committee

Upon a motion made by Commissioner Smith, seconded by Ms. Tandler, the Advisory Committee members voted in favor of funding application 544, GestVision, for up to \$500,000. VOTE: 8-0-0 (In favor: Mendelson, Smith, LaRochelle, McCooe, Tandler, Pezalla, Lee, Lalande).

- 547—MIFCOR

Dr. Cartiera introduced the proposed project. She discussed the experience of the team; the novel technology; the risks and benefits of the project; investments the company has received to date; and the strong possibility for CBIF's investment to be leveraged in the near term.

Dr. Cartiera noted that if this project is approved by the Committee, the motion should be contingent upon MIFCOR securing a license agreement from Yale as the company currently holds an exclusive option for license. A discussion ensued. Ms. Tandler suggested that CBIF have an understanding of employee commitments and review employment and stock agreements.

Upon a motion made by Commissioner Smith, seconded by Dr. LaRochelle, the Advisory Committee members voted in favor of funding application 547, MIFCOR, for up to \$500,000, contingent upon MIFCOR securing a license agreement from Yale University. VOTE: 8-0-0 (In favor: Mendelson, Smith, LaRochelle, McCooe, Tandler, Pezalla, Lee, Lalande).

Application Resubmissions

Dr. Lalande was excused from the discussion.

Dr. Cartiera discussed the current landscape in the field of genomics and emphasized that the Fund is seeing a growing number of opportunities in the bioinformatics space. She discussed current research and technology approaches within the discipline.

With this context in place, Dr. Cartiera reviewed the resubmission application submitted by Smpl Bio, originally received in Quarter 3 of 2014. She discussed the proposed goals and the associated risks and benefits. Dr. Cartiera highlighted the strides the company has made since the initial application with regard to product and team development including, modified approaches to the proposed work, partnership opportunities, and the recent hire of a full-time, experienced CEO.

A discussion ensued regarding Smpl Bio's approach and their capabilities in the field of single-cell analysis. Specific concerns were expressed by Dr. Lee regarding the scientific approach of the project and gaps on the team.

Connecticut Bioscience Innovation Fund Advisory Committee

The Committee unanimously agreed that all concerns should be sufficiently addressed before the proposed project is considered for funding. Dr. Cartiera stated that she would provide feedback to Smpl Bio.

Adjournment

Upon a motion made by Mr. Mendelson, seconded by Dr. Lee, the Advisory Committee members voted in favor of adjourning the meeting at 12:10 p.m. VOTE: 7-0-0 (In favor: Mendelson, Smith, Tandler, LaRochelle, McCooe, Pezalla, Lee).

Respectfully Submitted,

A handwritten signature in cursive script, appearing to read "Matt McCooe", written over a horizontal line.

Matthew McCooe, Chief Executive Officer
Connecticut Innovations